David Scholl
Medical · Carrollton, GANPI 1003811886
Payments from drug & device makers
Across 116 payments — averaging $32.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Pfizer$466
- Johnson & Johnson$242
- Incyte Corporation$140
- Daiichi Sankyo Inc.$126
- Merck$124
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,07155%
- Education$42111%
- Other$1,28034%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $1,427 |
| Pfizer | 21 | $466 |
| Johnson & Johnson | 5 | $242 |
| Incyte Corporation | 3 | $140 |
| Daiichi Sankyo Inc. | 5 | $126 |
| Merck | 5 | $124 |
| Eisai Inc. | 5 | $100 |
| AstraZeneca(2 entities) | 4 | $94 |
| Bayer | 4 | $94 |
| E.r. Squibb & Sons, L.L.C. | 5 | $86 |
| Seagen Inc. | 4 | $82 |
| Lilly USA, LLC | 3 | $75 |
| Exelixis Inc. | 3 | $65 |
| Gilead | 3 | $64 |
| GSK | 3 | $62 |
| AbbVie | 2 | $56 |
| Stemline Therapeutics Inc. | 3 | $52 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $47 |
| Genentech USA, Inc. | 2 | $46 |
| Caris MPI, Inc. | 1 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
| Geron Corporation | 1 | $27 |
| Deciphera Pharmaceuticals Inc. | 1 | $25 |
| Genentech, Inc. | 1 | $24 |
| Beigene USA, Inc. | 1 | $23 |
| Puma Biotechnology, Inc. | 1 | $22 |
| Sobi, Inc | 1 | $22 |
| Beone Medicines USA, Inc. | 1 | $22 |
| Sanofi | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
| Array Biopharma Inc | 1 | $12 |
| Bristol Myers Squibb | 1 | $12 |
How this compares
$3,772 in reported general payments places this provider in the 75th percentile of 950 medical providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 44 | $41,385 |
| XareltoRivaroxaban | 18 | $22,577 |
| Exemestane | 38 | $3,956 |
| Hydroxyurea | 43 | $1,334 |
| Anastrozole | 69 | $1,312 |
| Letrozole | 26 | $488 |
| Cyanocobalamin InjectionCyanocobalamin (Vitamin B-12) | 17 | $278 |
| Ondansetron Hcl | 18 | $260 |
| Ondansetron OdtOndansetron | 14 | $192 |
| Prednisone | 26 | $185 |
| Pantoprazole Sodium | 13 | $159 |
| Acyclovir | 13 | $158 |
| Prochlorperazine Maleate | 13 | $148 |
| Potassium Chloride | 15 | $132 |
| Doxycycline Hyclate | 11 | $99 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $466 | $41,38544 claims |
| Johnson & JohnsonXarelto | $242 | $22,57718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 950 medical providers in Georgia.
Other medical in Carrollton
- Tomas ChaoWoodstock$1.9M
- Kimberly OrleckAtlanta$727K
- Audrey GibsonGainesville$302K
- Lisa WeissCanton$283K
- Laura BushFayetteville$146K
- Michael KelleherMarietta$126K
- Juliena GigonMarietta$122K
- Felicia HoffmanRoswell$114K
- Sally BrumbillLithia Springs$110K
- Danna Dennis-CalderAtlanta$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.